|
1
|
Lara R, Seckl MJ and Pardo OE: The p90 RSK
family members: Common functions and isoform specificity. Cancer
Res. 17:5301–5308. 2013. View Article : Google Scholar
|
|
2
|
Romeo Y, Zhang X and Roux PP: Regulation
and function of the RSK family of protein kinases. Biochem J.
441:553–569. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kostenko S, Shiryaev A, Dumitriu G, Gerits
N and Moens U: Cross-talk between protein kinase A and the
MAPK-activated protein kinases RSK1 and MK5. J Recept Signal
Transduct Res. 31:1–9. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li D, Jin L, Alesi GN, Kim YM, Fan J, Seo
JH, Wang D, Tucker M, Gu TL, Lee BH, et al: The prometastatic
ribosomal S6 kinase 2-cAMP response element-binding protein
(RSK2-CREB) signaling pathway up-regulates the actin-binding
protein fascin-1 to promote tumor metastasis. J Biol Chem.
288:32528–32538. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Degen M, Barron P, Natarajan E, Widlund HR
and Rheinwald JG: RSK activation of translation factor eIF4B drives
abnormal increases of laminin γ2 and MYC protein during neoplastic
progression to squamous cell carcinoma. PLoS One. 8:e789792013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cohen JD, Babiarz JE, Abrams RM, Guo L,
Kameoka S, Chiao E, Taunton J and Kolaja KL: Use of human stem cell
derived cardiomyocytes to examine sunitinib mediated cardiotoxicity
and electrophysiological alterations. Toxicol Appl Pharmacol.
257:74–83. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Elf S, Blevins D, Jin L, Chung TW,
Williams IR, Lee BH, Lin JX, Leonard WJ, Taunton J, Khoury HJ and
Kang S: p90RSK2 is essential for FLT3-ITD-but dispensable for
BCR-ABL-induced myeloid leukemia. Blood. 117:6885–6894. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sak K and Everaus H: Chemomodulating
effects of flavonoids in human leukemia cells. Anticancer Agents
Med Chem. 15:1112–1126. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Morceau F, Chateauvieux S, Orsini M,
Trecul A, Dicato M and Diederich M: Natural compound and
pharmaceuticals reprogram leukemia cell differentiation pathways.
Biotechnol Adv. 33:(6 Pt 1). 785–797. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Humisto A, Herfindal L, Jokela J, Karkman
A, Bjornstad R, Choudhury RR and Sivonen K: Cyanobacteria as a
source for novel anti-leukemic compound. Curr Pharm Biotechnol.
17:78–91. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xu Y, Zhang J, Liu J, Li S, Li C, Wang W,
Ma R and Liu Y: Luteolin attenuate the d-galactose-induced renal
damage by attenuation of oxidative stress and inflammation. Nat
Prod Res. 29:1078–1082. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sung J and Lee J: Anti-inflammatory
activity of butein and luteolin through suppression of NFκB
activation and induction of heme oxygenase-1. J Med Food.
18:557–564. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Eumkeb G, Siriwong S and Thumanu K:
Synergistic activity of luteolin and amoxicillin combination
against amoxicillin-resistant Escherichia coli and mode of action.
J Photochem Photobiol B. 117:247–253. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kim YS, Kim SH, Shin J, Harikishore A, Lim
JK, Jung Y, Lyu HN, Baek NI, Choi KY, Yoon HS and Kim KT: Luteolin
suppresses cancer cell proliferation by targeting vaccinia-related
kinase 1. PLoS One. 9:e1096552014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Park SH, Ham S, Kwon TH, Kim MS, Lee DH,
Kang JW, Oh SR and Yoon DY: Luteolin induces cell cycle arrest and
apoptosis through extrinsic and intrinsic signaling pathways in
MCF-7 breast cancer cells. J Environ Pathol Toxicol Oncol.
33:219–231. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chian S, Li YY, Wang XJ and Tang XW:
Luteolin sensitizes two oxaliplatin-resistant colorectal cancer
cell lines to chemotherapeutic drugs via inhibition of the Nrf2
pathway. Asian Pac J Cancer Prev. 15:2911–2916. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen KC, Chen CY, Lin CR, Yang TY, Chen
TH, Wu LC and Wu CC: Luteolin attenuates TGF-β1-induced
epithelial-mesenchymal transition of lung cancer cells by
interfering in the PI3K/Akt-NF-κB-Snail pathway. Life Sci.
93:924–933. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Reipas KM, Law JH, Couto N, Islam S, Li Y,
Li H, Cherkasov A, Jung K, Cheema AS, Jones SJ, et al: Luteolin is
a novel p90 ribosomal S6 kinase (RSK) inhibitor that suppresses
Notch4 signaling by blocking the activation of Y-box binding
protein-1 (YB-1). Oncotarget. 4:329–345. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Falini B, Tiacci E, Martelli MP, Ascani S
and Pileri SA: New classification of acute myeloid leukemia and
precursor-related neoplasms: Changes and unsolved issues. Discov
Med. 10:281–292. 2010.PubMed/NCBI
|
|
20
|
Flygare J, Kiefer T, Miyake K, Utsugisawa
T, Hamaguchi I, Da Costa L, Richter J, Davey EJ, Matsson H, Dahl N,
et al: Deficency of ribosomal protein S19 in CD34+ cells generated
by siRNA blocks erythroid development and mimics defected seen in
Diamond-Blackfan anemia. Blood. 105:4627–4634. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sun D, Huang J, Zhang Z, Gao H, Li J, Shen
M, Cao F and Wang H: Luteolin limits infarct size and improves
cardiac function after myocardium ischemia/reperfusion injury in
diabetic rats. PLoS One. 7:e334912012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lee WR, Shen SC, Lin HY, Hou WC, Yang LL
and Chen YC: Wogonin and fisetin induce apoptosis in human
promyeloleukemic cells, accompanied by a decrease of reactive
oxygen species, and activation of caspase 3 and
Ca2+-dependent endonuclease. Biochem Pharmacol.
63:225–236. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Friday BB and Adjei AA: Advances in
targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase
cascade with MEK inhibitors for cancer therapy. Clin Cancer Res.
14:342–346. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Crudden C, Ilic M, Suleymanova N, Worrall
C, Girnita A and Girnita L: The dichotomy of the Insulin-like
growth factor 1 receptor: RTK and GPCR: Friend or foe for cancer
treatment? Growth Horm IGF Res. 25:2–12. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sabine VS, Crozier C, Brookes CL, Drake C,
Piper T, van de Velde CJ, Hasenburg A, Kieback DG, Markopoulos C,
Dirix L, et al: Mutational analysis of PI3K/AKT signaling pathway
in tamoxifen exemestane adjuvant multinational pathology study. J
Clin Oncol. 32:2951–2958. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Johnson AS, Crandall H, Dahlman K and
Kelley MC: Preliminary results from a prospective trial of
preoperative combined BRAF and MEK-targeted therapy in advanced
BRAF mutation-positive melanoma. J Am Coll Surg. 220:581–593.e1.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dent P: Arsenic in leukemia: A RSKy
business. Cancer Biol Ther. 14:871–872. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yu G, Lee YC, Cheng CJ, Wu CF, Song JH,
Gallick GE, Yu-Lee LY, Kuang J and Lin SH: RSK promotes prostate
cancer progression in bone through ING3, CKAP2, and PTK6-mediated
cell survival. Mol Cancer Res. 13:348–357. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Stratford AL, Reipas K, Hu K, Fotovati A,
Brough R, Frankum J, Takhar M, Watson P, Ashworth A, Lord CJ, et
al: Targeting p90 ribosomal S6 kinase eliminates tumor-initiating
cells by inactivating Y-box binding protein-1 in triple-negative
breast cancers. Stem Cells. 30:1338–1348. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Goulet AC, Watts G, Lord JL and Nelson MA:
Profiling of selenomethionine responsive genes in colon cancer by
microarray analysis. Cancer Biol Ther. 6:494–503. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sato Y, Sasaki N, Saito M, Endo N, Kugawa
F and Ueno A: Luteolin attenuates doxorubicin-induced cytotoxicity
to mcf-7 human breast cancer cells. Biol Pharm Bull. 38:703–709.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bumke-Vogt C, Osterhoff MA, Borchert A,
Guzman-Perez V, Sarem Z, Birkenfeld AL, Bähr V and Pfeiffer AF: The
flavones apigenin and luteolin induce FOXO1 translocation but
inhibit gluconeogenic and lipogenic gene expression in human cells.
PLoS One. 9:e1043212014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chian S, Thapa R, Chi Z, Wang XJ and Tang
X: Luteolin inhibits the Nrf2 signaling pathway and tumor growth in
vivo. Biochem Biophys Res Commun. 447:602–608. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Thimmaiah KN, Easton JB and Houghton PJ:
Protection from rapamycin-induced apoptosis by insulin-like growth
factor-I is partially dependent on protein kinase C signaling.
Cancer Res. 70:2000–2009. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Czaplinska D, Turczyk L, Grudowska A,
Mieszkowska M, Lipinska AD, Skladanowski AC, Zaczek AJ, Romanska HM
and Sadej R: Phosphorylation of RSK2 at Tyr529 by FGFR2-p38
enhances human mammary epithelial cells migration. Biochim Biophys
Acta. 1843:2461–2470. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yang S, Ji M, Zhang L, Chen Y, Wennmann
DO, Kremerskothen J and Dong J: Phosphorylation of KIBRA by the
extracellular signal-regulated kinase (ERK)-ribosomal S6 kinase
(RSK) cascade modulates cell proliferation and migration. Cell
Signal. 26:343–351. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Xiao L, Chen Y, Ji M and Dong J: KIBRA
regulates Hippo signaling activity via interactions with large
tumor suppressor kinases. J Biol Chem. 286:7788–7796. 2011.
View Article : Google Scholar : PubMed/NCBI
|
